GeneDx Holdings Corp. (NASDAQ:WGS) Major Shareholder Opko Health, Inc. Sells 88,839 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) major shareholder Opko Health, Inc. sold 88,839 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $33.50, for a total transaction of $2,976,106.50. Following the sale, the insider now directly owns 2,984,564 shares in the company, valued at approximately $99,982,894. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Opko Health, Inc. also recently made the following trade(s):

• On Monday, July 29th, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The stock was sold at an average price of $33.86, for a total transaction of $1,693,000.00.
• On Friday, July 26th, Opko Health, Inc. sold 60,000 shares of GeneDx stock. The stock was sold at an average price of $33.85, for a total transaction of $2,031,000.00.
• On Wednesday, July 24th, Opko Health, Inc. sold 75,000 shares of GeneDx stock. The stock was sold at an average price of $33.72, for a total transaction of $2,529,000.00.
• On Monday, July 22nd, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The stock was sold at an average price of $32.61, for a total transaction of $1,630,500.00.
• On Friday, July 19th, Opko Health, Inc. sold 25,000 shares of GeneDx stock. The stock was sold at an average price of $32.29, for a total transaction of $807,250.00.
• On Wednesday, July 17th, Opko Health, Inc. sold 25,000 shares of GeneDx stock. The stock was sold at an average price of $32.93, for a total transaction of $823,250.00.
• On Friday, July 5th, Opko Health, Inc. sold 36,118 shares of GeneDx stock. The shares were sold at an average price of $28.24, for a total transaction of $1,019,972.32.
• On Wednesday, July 3rd, Opko Health, Inc. sold 14,082 shares of GeneDx stock. The shares were sold at an average price of $28.23, for a total transaction of $397,534.86.
• On Monday, July 1st, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The shares were sold at an average price of $26.63, for a total transaction of $1,331,500.00.

GeneDx Trading Down 6.8 %

Shares of WGS stock opened at $30.07 on Monday. GeneDx Holdings Corp. has a 52-week low of $1.16 and a 52-week high of $35.65. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.99 and a current ratio of 2.38. The company has a 50-day simple moving average of $28.43 and a two-hundred day simple moving average of $16.70. The company has a market capitalization of $785.43 million, a price-to-earnings ratio of -5.81 and a beta of 2.29.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on WGS shares. The Goldman Sachs Group boosted their target price on shares of GeneDx from $28.00 to $32.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. BTIG Research boosted their target price on shares of GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Jefferies Financial Group initiated coverage on shares of GeneDx in a research note on Monday, June 3rd. They issued a “hold” rating and a $21.00 price target for the company. TD Cowen lifted their price target on shares of GeneDx from $46.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Finally, Craig Hallum lifted their price target on shares of GeneDx from $43.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.80.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new position in GeneDx in the second quarter valued at about $50,000. PFG Investments LLC purchased a new position in GeneDx in the first quarter valued at about $95,000. Rhumbline Advisers boosted its stake in GeneDx by 8,096.4% in the second quarter. Rhumbline Advisers now owns 18,360 shares of the company’s stock valued at $480,000 after acquiring an additional 18,136 shares during the last quarter. Legal Advantage Investments Inc. purchased a new position in GeneDx in the second quarter valued at about $518,000. Finally, Thompson Davis & CO. Inc. boosted its stake in GeneDx by 99.4% in the fourth quarter. Thompson Davis & CO. Inc. now owns 19,944 shares of the company’s stock valued at $55,000 after acquiring an additional 9,944 shares during the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.